Commentary: Treatment of lichen planopilaris

Sperling, Leonard C.; Nguyen, Jennifer

doi:10.1016/j.jaad.2009.10.025

Cited by 22 publications

(6 citation statements)

References 20 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapeutic management of LPP is challenging with current therapeutic options failing to alleviate active inflammation and prevent disease progression. [1][2][3] Most remarkably, improvement of hair regrowth and reduction in inflammation of LPP patches were observed in this case.…”

Section: Discussionsupporting

confidence: 66%

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis

Alam

LaBelle

2020

JAAD Case Reports

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 66%

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis

Alam

LaBelle

2020

JAAD Case Reports

View full text Add to dashboard Cite

“…Intralesional and topical corticosteroids are considered the first-line treatments for LPP. 21 They can be used as monotherapy or associated with other drugs with varying degrees of success. They are indicated in localized lesions of a limited extent.…”

Section: Treatmentmentioning

confidence: 99%

“…Some of them are systemic retinoids, tetracyclines, thalidomide, dapsone, pioglitazone, topical calcineurin inhibitors, griseofulvin. 21 , 25 , 30 …”

Section: Treatmentmentioning

confidence: 99%

Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features

Fechine

Valente

Romiti

2022

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

“…Treatment options are limited and yield inconsistent results [2]. Topical and intralesional corticosteroids are generally considered first-line [2,3]. Other treatments include oral hydroxychloroquine [4] and doxycycline [2].…”

Section: Introductionmentioning

confidence: 99%

Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study

Hamel¹,

Chen²,

O’Connell³

et al. 2023

Cureus

View full text Add to dashboard Cite

BackgroundFrontal fibrosing alopecia (FFA) and lichen planopilaris (LPP) is scarring alopecias with limited evidence supporting their treatment options. We investigated the use of low-dose naltrexone (3 mg oral daily) as adjunctive therapy in the treatment of FFA and LPP. MethodsA single-center, uncontrolled open-label prospective study was performed, with 26 patients who took lowdose naltrexone for one year included in the per-protocol analysis. Both patient-reported (pruritus and burning/pain) and physician-assessed (erythema, scale, and scalp involvement) outcomes were analyzed. ResultsThere were decreases in erythema and scale for the overall longitudinal outcomes using linear mixed effects model analysis. However, only erythema had a significant decrease at 12 months compared with baseline. Mean erythema decreased by 0.93 at 12 months compared with baseline on a 0-3-point scale (p<0.0001, 95% mean CI [-1.32, -0.53]). There was no statistically significant difference comparing 12 months to baseline for the other outcomes including pruritus, burning/pain, and scalp involvement. Limitations include the possibility of spontaneous stabilization, concurrent medications, a small sample size with limited racial diversity, and mild subjective symptoms at baseline. ConclusionOur study supports further investigation of oral low-dose naltrexone as adjunctive therapy in the treatment of FFA and LPP if there is prominent erythema, and possibly scale.

show abstract

Commentary: Treatment of lichen planopilaris

Cited by 22 publications

References 20 publications

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis

Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features

Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study

Contact Info

Product

Resources

About